Suppr超能文献

脂肪来源干细胞衍生的外泌体可预防药物相关性颌骨坏死。

Exosomes from Adipose-Derived Stem Cells Can Prevent Medication-Related Osteonecrosis of the Jaw.

机构信息

Laboratory of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China (mainland).

First Clinical Division, Peking University School Hospital of Stomatology, Beijing, China (mainland).

出版信息

Med Sci Monit. 2021 Mar 10;27:e929684. doi: 10.12659/MSM.929684.

Abstract

The treatment measures of medication-related osteonecrosis of the jaw (MRONJ) is a worldwide challenge in oral and maxillofacial surgery because of its unclear pathogenesis. Previous studies suggested that mesenchymal stem cells played important roles in promoting MRONJ lesion healing, but the detailed mechanisms were unknown. Increasing numbers of studies have demonstrated that exosomes derived from mesenchymal stem cells, especially adipose-derived stem cells, have key roles in stem cell-based therapies by accelerating bone remodeling, facilitating angiogenesis, and promoting wound healing. We hypothesized that exosomes derived from adipose-derived stem cells can prevent MRONJ by accelerating gingival healing and enhancing bone remodeling processes. Our results may provide a promising therapeutic option for MRONJ clinical therapy.

摘要

药物相关性颌骨坏死(MRONJ)的治疗措施是口腔颌面外科学领域的全球性挑战,因为其发病机制尚不清楚。先前的研究表明,间充质干细胞在促进 MRONJ 病变愈合方面发挥着重要作用,但具体机制尚不清楚。越来越多的研究表明,间充质干细胞来源的外泌体,特别是脂肪来源的干细胞,通过加速骨重塑、促进血管生成和促进伤口愈合,在基于干细胞的治疗中发挥着关键作用。我们假设脂肪来源干细胞衍生的外泌体可以通过加速牙龈愈合和增强骨重塑过程来预防 MRONJ。我们的研究结果可能为 MRONJ 的临床治疗提供一种有前途的治疗选择。

相似文献

引用本文的文献

5
Treatment of medication-related osteonecrosis of the jaw with cell therapy.采用细胞疗法治疗药物相关性颌骨坏死。
Front Cell Dev Biol. 2024 Jan 26;12:1338376. doi: 10.3389/fcell.2024.1338376. eCollection 2024.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验